Table 1.
Characteristics of patient groups that completed treatment (baseline data)
| Characteristics of patient groups | Placebo | Doxycycline (4 weeks) | Doxycycline (6 weeks) |
|---|---|---|---|
| Baseline data | |||
| No. of individuals | 23 | 22 | 22 |
| Sex ratio, male/female | 15/8 | 18/4 | 18/4 |
| Mean age, years (range) |
39 (20–61) |
39 (23–58) |
41 (19–59) |
| Mean weight, kg (range) |
54 (40–67) |
54 (49–65) |
56 (40–73) |
|
No. of palpable nodules Median (range) |
5 (2–13) |
6 (2–13) |
5 (2–13) |
| No. of mf carriers | 20 | 20 | 22 |
|
No. of mf/mg in the skin Median (range) |
9 (0–98) |
6 (0–78) |
21 (2–175) |
| No. with onchodermatitis | 1 | 5 | 7 |
| No. with depigmentation | 2 | 8 | 3 |
|
No. of individuals who took previously ivermectina Months before recruitment Mean (range) |
16 18 (5–41) |
8 15 (1–41) |
14 19 (5–40) |
|
No. with complete treatment Less days of treatment |
22 1 × 28 |
20 2 × 41b |
19 1 × 40, 2 × 41 |
aThree patients had taken ivermectin two times before study onset; the rest had taken ivermectin a single time
bThe 1 day that the two patients missed was during the doxycycline part of the treatment